Results 91 to 100 of about 46,843 (269)

Maculopapular eruption secondary to itraconazole

Collegium antropologicum, 2008
Adverse cutaneous reactions to itraconazole are known to be quite rare. We report a case of maculopapular reaction caused by itraconazole. On the 7th day of itraconazole therapy for hand onychomycosis, in a 39-year-old woman pruritus occurred with a subsequent morbiliform, symmetric, maculopapular eruption on the upper torso, neck, trunk and pressure ...
Batinac, Tanja, Zamolo, Gordana, Trošelj-Vukić, Biserka, Biljan, Darko, Petranović, Duška, Kujundžić, Milodar   +5 more
openaire   +5 more sources

Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450

British Journal of Clinical Pharmacology, Volume 91, Issue 8, Page 2316-2326, August 2025.
Aims To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel])
Vivek S. Purohit, Yeamin Huh, Martin E. Dowty, Anna Plotka, Alexandre Lejeune, Hindu Kalluru, Brian Hee   +6 more
wiley   +1 more source

Itraconazole promotes melanoma cells apoptosis via inhibiting hedgehog signaling pathway-mediated autophagy

Frontiers in Pharmacology
BackgroundItraconazole, a widely used antifungal medication, has shown potential in inhibiting tumor growth and reducing angiogenesis. However, its role in melanoma tumor growth remains insufficiently explored.
Shunqiao Jin, Shunqiao Jin, Xiaojiao Liu, Xiaojiao Liu, Lingqin Cai, Lingqin Cai, Jiayu Yan, Ling Li, Hongjun Dong, Yuxue Gao, Xicong Zhu, Cong Zhang, Xuezhu Xu   +12 more
doaj   +1 more source

Desenvolvimento e validação de metodologia analítica para determinação de itraconazol em produtos farmacêuticos por CLAE Development and validation of the methodology for evaluation of itraconazole in pharmaceutical products by HPLC

Química Nova, 2007
Itraconazole is a synthetic antifungal drug administered orally with a broad spectrum of activity against mycotic infections. The present work consists of the development and validation of analytical methodology for evaluation of itraconazole in ...
Edith Cristina Laignier Cazedey, Roberta de Cássia Pimentel Azevedo, Érika de Fátima Silva, Magali Benjamim de Araújo   +3 more
doaj   +1 more source

Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats

Journal of Toxicology, 2017
Oral ketoconazole was recently the subject of regulatory safety warnings because of its association with increased risk of inducing hepatic injury. However, the relative hepatotoxicity of antifungal agents has not been clearly established.
S. Khoza, Ishmael Moyo, Denver Ncube
semanticscholar   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, Volume 14, Issue 8, Page 605-613, August 2025.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, Volume 14, Issue 8, Page 631-641, August 2025.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

Heart failure induced by itraconazole

Indian Journal of Pharmacology, 2013
Itraconazole is a broad-spectrum antifungal agent. It rarely leads to adverse the cardiovascular effects, especially heart failure. We present here a case of a 60-year-old female patient with itraconazole induced heart failure.
Hizir Okuyan, Cihan Altin
openaire   +3 more sources

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

The Journal of Clinical Pharmacology, Volume 65, Issue 8, Page 1026-1038, August 2025.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller, Lauren Lohmer, Felix Beck, Jeegar Patel, Jasminder Sahi   +4 more
wiley   +1 more source

Treatment of invasive aspergillosis with itraconazole

The American Journal of Medicine, 1989
Invasive aspergillosis in the immunocompromised host is one of the most difficult therapeutic problems. Itraconazole, a new oral triazole, is inhibitory as well as fungicidal against Aspergillus species in vitro. It is active against Aspergillus infections in animal models.
Denning, D.W., Tucker, R.M., Hansen, L.H., Stevens, D.A.   +3 more
openaire   +3 more sources